Cytokine regulation of apoptosis-induced apoptosis and apoptosis-induced cell proliferation in vascular smooth muscle cells.
Animals
Apoptosis
/ genetics
Blood Vessels
/ growth & development
Cell Proliferation
/ genetics
Cells, Cultured
Cytokines
/ genetics
Gene Expression Regulation, Developmental
/ drug effects
Granulocyte-Macrophage Colony-Stimulating Factor
/ genetics
Heparin-binding EGF-like Growth Factor
/ genetics
Humans
Interleukin-6
/ genetics
MAP Kinase Kinase 4
/ genetics
Mice
Muscle, Smooth, Vascular
/ cytology
Myocytes, Smooth Muscle
/ cytology
Oncogene Protein v-akt
/ genetics
Signal Transduction
/ drug effects
Staurosporine
/ pharmacology
fas Receptor
/ genetics
p38 Mitogen-Activated Protein Kinases
/ genetics
Apoptosis
Cytokine
Proliferation
Vascular smooth muscle
Journal
Apoptosis : an international journal on programmed cell death
ISSN: 1573-675X
Titre abrégé: Apoptosis
Pays: Netherlands
ID NLM: 9712129
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
7
7
2020
medline:
31
7
2021
entrez:
7
7
2020
Statut:
ppublish
Résumé
Vascular smooth muscle cells (VSMCs) are the main structural cell of blood vessels, and VSMC apoptosis occurs in vascular disease, after injury, and in vessel remodeling during development. Although VSMC apoptosis is viewed as silent, recent studies show that apoptotic cells can promote apoptosis-induced compensatory proliferation (AICP), apoptosis-induced apoptosis (AIA), and migration of both local somatic and infiltrating inflammatory cells. However, the effects of VSMC apoptosis on adjacent VSMCs, and their underlying signaling and mechanisms are unknown. We examined the consequences of VSMC apoptosis after activating extrinsic and intrinsic death pathways. VSMCs undergoing apoptosis through Fas/CD95 or the protein kinase inhibitor staurosporine transcriptionally activated interleukin 6 (IL-6) and granulocyte-macrophage colony stimulating factor (GM-CSF), leading to their secretion. Apoptosis induced activation of p38MAPK, JNK, and Akt, but neither p38 and JNK activation nor IL-6 or GM-CSF induction required caspase cleavage. IL-6 induction depended upon p38 activity, while Fas-induced GM-CSF expression required p38 and JNK. Conditioned media from apoptotic VSMCs induced VSMC apoptosis in vitro, and IL-6 and GM-CSF acted as pro-survival factors for AIA. VSMC apoptosis was studied in vivo using SM22α-DTR mice that express the diphtheria toxin receptor in VSMCs only. DT administration induced VSMC apoptosis and VSMC proliferation, and also signficantly induced IL-6 and GM-CSF. We conclude that VSMC apoptosis activates multiple caspase-independent intracellular signaling cascades, leading to release of soluble cytokines involved in regulation of both cell proliferation and apoptosis. VSMC AICP may ameliorate while AIA may amplify the effects of pro-apoptotic stimuli in vessel remodeling and disease.
Identifiants
pubmed: 32627119
doi: 10.1007/s10495-020-01622-4
pii: 10.1007/s10495-020-01622-4
pmc: PMC7527356
doi:
Substances chimiques
Cytokines
0
Heparin-binding EGF-like Growth Factor
0
Interleukin-6
0
fas Receptor
0
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Oncogene Protein v-akt
EC 2.7.11.1
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
MAP Kinase Kinase 4
EC 2.7.12.2
Staurosporine
H88EPA0A3N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
648-662Subventions
Organisme : British Heart Foundation
ID : RG/16/8/32388
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/13/3/30038
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/19/33371
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/13/25/30014
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/20/2/34763
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/11/32021
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/2000003/12800
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/24/32090
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/63/32307
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/14/30314
Pays : United Kingdom
Références
J Biol Chem. 1998 Jul 24;273(30):19207-12
pubmed: 9668108
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2402-9
pubmed: 21885847
Int J Mol Sci. 2017 Nov 29;18(12):
pubmed: 29186034
Arterioscler Thromb Vasc Biol. 1997 May;17(5):1003-9
pubmed: 9157967
J Clin Invest. 2002 Feb;109(4):437-41
pubmed: 11854313
Circulation. 1998 Oct 20;98(16):1657-65
pubmed: 9778332
Cold Spring Harb Perspect Biol. 2012 Aug 01;4(8):a008797
pubmed: 22855725
Exp Cell Res. 1994 Apr;211(2):314-21
pubmed: 8143779
Nat Med. 2011 Jul 03;17(7):860-6
pubmed: 21725296
Circ Res. 2010 Feb 5;106(2):363-72
pubmed: 19926874
Molecules. 2019 Apr 10;24(7):
pubmed: 30974824
PLoS One. 2017 May 22;12(5):e0178063
pubmed: 28531207
Semin Cell Dev Biol. 2018 Oct;82:86-95
pubmed: 29199139
Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):19-27
pubmed: 8548421
FASEB J. 2000 Feb;14(2):261-70
pubmed: 10660448
Sci Signal. 2010 Feb 23;3(110):ra13
pubmed: 20179271
J Immunol. 1999 Oct 15;163(8):4583-9
pubmed: 10510402
Am J Pathol. 2006 Jun;168(6):2054-63
pubmed: 16723718
J Biol Chem. 2010 Aug 27;285(35):27429-39
pubmed: 20562100
Curr Top Dev Biol. 2014;108:121-51
pubmed: 24512708
J Biol Chem. 1999 Aug 13;274(33):23013-9
pubmed: 10438468
Mol Cell Endocrinol. 2003 May 30;203(1-2):77-90
pubmed: 12782405
Am J Physiol Endocrinol Metab. 2003 May;284(5):E972-9
pubmed: 12527559
J Cell Biol. 2011 Jan 10;192(1):171-88
pubmed: 21220513
Immunol Cell Biol. 2009 Feb;87(2):122-30
pubmed: 18839015
J Immunol. 2004 Nov 15;173(10):6409-17
pubmed: 15528381
Nat Rev Mol Cell Biol. 2015 Jun;16(6):329-44
pubmed: 25991373
Circ Res. 1997 Sep;81(3):328-37
pubmed: 9285634
J Vasc Res. 1999 Mar-Apr;36(2):120-5
pubmed: 10213907
Atherosclerosis. 1999 May;144(1):25-32
pubmed: 10381274
Cell Death Dis. 2017 May 25;8(5):e2818
pubmed: 28542133
Neurosci Res. 2007 May;58(1):50-7
pubmed: 17331604
Am J Physiol. 1991 May;260(5 Pt 2):H1713-7
pubmed: 1709793
Elife. 2013 Sep 24;2:e01004
pubmed: 24066226
Science. 2005 Dec 2;310(5753):1504-10
pubmed: 16293724
Dev Cell. 2004 Oct;7(4):491-501
pubmed: 15469838
Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1624-30
pubmed: 12377740
Proteomics Clin Appl. 2018 Sep;12(5):e1700097
pubmed: 29687628
Front Immunol. 2017 Sep 27;8:1216
pubmed: 29021794
Br J Pharmacol. 2000 Mar;129(5):835-8
pubmed: 10696078
Circ Res. 1995 Feb;76(2):168-75
pubmed: 7834826
Nat Med. 2000 Jul;6(7):790-6
pubmed: 10888928
Biochem Res Int. 2012;2012:453838
pubmed: 22919490
Br J Pharmacol. 1997 Mar;120(5):910-6
pubmed: 9138698
PLoS One. 2015 Oct 21;10(10):e0141375
pubmed: 26488175
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1553-8
pubmed: 12869351
EMBO J. 1995 Jan 16;14(2):266-75
pubmed: 7835337
Circ Res. 2008 Jun 20;102(12):1529-38
pubmed: 18497329
Nat Med. 2006 Sep;12(9):1075-80
pubmed: 16892061
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2489-99
pubmed: 9409219